Novartis logo displayed on a building, symbolizing UK cholesterol study delays - Global Banking & Finance Review
Image showing the Novartis logo, reflecting the pharmaceutical company's decision to postpone its UK cholesterol study's conclusion to 2026 due to COVID-19 disruptions. This highlights the impact of the pandemic on critical health research.
Business

Novartis pushes back UK cholesterol study’s end to 2026 on COVID disruption

Published by linker 5

Posted on April 27, 2021

· Last updated: January 21, 2026

Add as preferred source on Google

Related Articles

More from Business

Explore more articles in the Business category